证券代码：688480 证券简称：赛恩斯 公告编号： 2024-043 赛恩斯环保股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 10 月 15 日(星期二)上午 10:00-11:00 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 10 月 08 日(星期二)至 10 月 14 日(星期一)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 seshb_cn@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 赛恩斯环保股份有限公司（以下简称"公司"）已于 2024 年 8 月 27 日发布 公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年 ...

赛恩斯环保股份有限公司 关于控股股东增持公司股份计划的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688480 证券简称：赛恩斯 公告编号：2024-042 （一）增持目的：基于对公司长期投资价值的认可及未来持续稳定发展的 信心。 重要内容提示： 公司控股股东高伟荣先生基于对赛恩斯环保股份有限公司（以下简称 "公司"）长期投资价值的认可及未来持续稳定发展的信心，拟使用自筹资 金，自 2024 年 9 月 30 日起 6 个月内，通过上海证券交易所交易系统允许的方 式（包括但不限于集中竞价、连续竞价、大宗交易等）增持公司无限售条件流 通 A 股股票，增持金额不低于人民币 2,000 万元（含）且不高于人民币 3,000 万元（含）。 相关风险提示：本次增持计划可能存在因证券市场情况发生变化或政策 因素等导致增持计划无法实施的风险。如增持计划实施过程中出现相关风险情 形，公司将及时履行信息披露义务。 高伟荣先生在实施本次增持计划的过程中，将遵守中国证券监督管理委 员会、上海证券交易所关于上市公司权益变动及股 ...

申万宏源证券承销保荐有限责任公司 关于赛恩斯环保股份有限公司 2024年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上 市规则》等有关法律法规的规定，申万宏源证券承销保荐有限责任公司（以下简 称"申万宏源承销保荐"或"保荐机构"）作为赛恩斯环保股份有限公司（以下简称 "赛恩斯"、"公司"）首次公开发行股票并在科创板上市持续督导阶段的保荐机构， 负责赛恩斯上市后的持续督导工作，并出具2024年半年度持续督导跟踪报告。 | 序 | 工作内容 | 持续督导工作情况 | | --- | --- | --- | | 号 | | | | 1 | 建立健全并有效执行持续督导工作制度， | 保荐机构已建立健全并有效执行持续督导 | | | 并针对具体的持续督导工作制定相应的 | 工作制度，并制定了相应工作计划 | | | 工作计划 | | | | 根据中国证监会相关规定，在持续督导工 | | | 2 | 作开始前，与上市公司或相关当事人签署 | 保荐机构已与赛恩斯签订了保荐协议（明 | | | 持续督导协议，明确双方在持续督导期间 | 确双方在持续督导期间的权利义务） | | | ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 23.72 RMB [5] Core Views - The company achieved significant revenue and profit growth in H1 2024, with revenue reaching 356 million RMB (+32.68% YoY) and net profit attributable to shareholders of 115 million RMB (+216.75% YoY) [1] - The company's "three-in-one" business model (solutions, product sales, and operation services) drives synergistic growth, with operation services contributing 37% of total revenue [2] - The acquisition of Zijin Pharmaceutical enhances the company's product moat and technological barriers, supporting global expansion [3] Business Performance - Heavy metal pollution prevention solutions: Revenue of 105 million RMB (-15.8% YoY), accounting for 29% of total revenue, with seasonal revenue recognition expected in H2 [2] - Product sales: Revenue of 117 million RMB (+109.8% YoY), contributing 33% of total revenue, driven by the consolidation of Zijin Pharmaceutical [2] - Operation services: Revenue of 131 million RMB (+54.1% YoY), representing 37% of total revenue [2] Financial Forecasts - Revenue is expected to grow from 1.16 billion RMB in 2024E to 1.90 billion RMB in 2026E, with a CAGR of 32.15% [4] - Net profit attributable to shareholders is projected to increase from 201.65 million RMB in 2024E to 276.90 million RMB in 2026E [4] - EPS is forecasted to rise from 2.12 RMB in 2024E to 2.90 RMB in 2026E [4] Valuation Metrics - The company's P/E ratio is 11.21x for 2024E, 10.21x for 2025E, and 8.17x for 2026E [4] - EV/EBITDA is expected to decline from 6.23x in 2024E to 3.55x in 2026E [4] Shareholder and Industry Impact - The company benefits from the continuous support of its second-largest shareholder, Zijin Mining, with related transactions expected to reach 450 million RMB in 2024 [3] - The company is positioned as a leader in the heavy metal pollution prevention and resource utilization sector, with strong R&D capabilities and partnerships with academic institutions [4]

证券简称：赛恩斯 证券代码：688480 赛恩斯环保股份有限公司 投资者关系活动记录表 编号：2024-007 | --- | --- | --- | --- | |------------------|--------------------------|-------------------------------------------------|-------------| | | | | | | | □ | 特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | | □ 新闻发布会 □路演活动 | | | | 类别 | 现场参观 | | | | | | 其他（请文字说明其他活动内容） 投资者电话交流会 | | | 参与单位名称 | 1 、长江证券及其他投资者 | 7 人 | | | | 2 、东吴证券及其他投资者 | 14 人 | | | 及人员姓名 | 3 、华泰证券及其他投资者 | 8 人 | | | | 1、2024 年 8 月 | 27 日（周二） | 15:00-16:00 | | 时间 | 2、2024 年 8 月 | 28 日（周三） | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][7]. Core Insights - The company reported a revenue of 356 million yuan for H1 2024, representing a year-on-year growth of 32.68%. The net profit attributable to the parent company reached 115 million yuan, a significant increase of 216.75%. The net profit after deducting non-recurring gains and losses was 54.09 million yuan, up by 64.97% year-on-year. The overall gross margin improved to 37.09%, an increase of 3.74 percentage points compared to H1 2023 [1][3]. Financial Performance Summary - Revenue Breakdown: - Comprehensive solutions: 105 million yuan, down 15.78% year-on-year - Product sales: 117 million yuan, up 109.77% year-on-year - Operational services: 131 million yuan, up 54.08% year-on-year [3]. - Gross Margin Analysis: - Comprehensive solutions: 30.58%, up 7.87 percentage points - Product sales: 45.03%, down 0.27 percentage points - Operational services: 34.73%, up 1.95 percentage points [3]. - Investment Income: - The company achieved investment income of 61.72 million yuan, primarily from the acquisition of Fujian Zijin Reagent Co., which contributed 59.29 million yuan in investment income due to fair value remeasurement [1][3]. Future Earnings Forecast - Projected revenues for 2024-2026 are estimated at 1.192 billion yuan, 1.545 billion yuan, and 1.776 billion yuan, respectively, with corresponding net profits of 212 million yuan, 228 million yuan, and 290 million yuan. The expected growth rates for net profit are 135%, 7%, and 27% for the respective years [5][7]. - The company maintains a competitive advantage and is expected to achieve high growth in performance, justifying the "Buy" rating [4][5].

Investment Rating - The report maintains a "Buy" rating for the company [1][3] Core Views - The company achieved a revenue of 356 million yuan in the first half of 2024, representing a year-on-year growth of 32.68%, and a net profit attributable to shareholders of 115 million yuan, up 216.75% year-on-year [2][3] - The improvement in revenue structure and the increase in gross margin are driven by a higher proportion of product sales and operational service income [2][3] - The acquisition of Zijin Reagent in February 2024 contributed 59.29 million yuan in investment income, enhancing the company's product sales [2][3] Summary by Sections Financial Performance - Total revenue for 2024 is projected to reach 1,154.25 million yuan, with a year-on-year growth of 42.78% [1] - The net profit attributable to shareholders is expected to be 202.13 million yuan in 2024, reflecting a significant increase of 123.78% year-on-year [1] - The company’s EPS is forecasted to be 2.12 yuan per share in 2024, with a P/E ratio of 11.44 [1] Revenue Breakdown - The revenue from operational services increased by 54.1% year-on-year, accounting for 36.88% of total revenue [2] - Product sales, including reagent products and copper extraction agents, saw a substantial increase of 109.8% year-on-year, making up 32.88% of total revenue [2] - The comprehensive solution for heavy metal pollution prevention generated 105 million yuan in revenue, down 15.8% year-on-year, indicating a need for further transformation into product sales and operational services [2] Strategic Developments - The company is deepening its collaboration with Zijin Mining, with related revenue in the first half of 2024 reaching 83 million yuan, a 14.1% increase year-on-year [2] - The implementation of an equity incentive plan aims to motivate core personnel and attract talent, with revenue targets set at 1.1 billion yuan and 1.5 billion yuan for 2024 and 2025, respectively [3]

赛恩斯环保股份有限公司 关于 2024 年"提质增效重回报"行动方案 的半年度评估报告 赛恩斯环保股份有限公司（以下简称"公司"）为发挥上市公司的主体责任， 更好的回报投资者，基于对行业与公司长期发展前景的信心，结合公司发展战 略与 2024 年经营计划，制定公司 2024 年度"提质增效重回报"行动方案（以 下简称"行动方案"）。截至 2024 年 6 月 30 日，行动方案主要举措的落实（进 展）及成效情况如下： 一、公司业务发展情况 2024 年上半年，公司实现营业收入 35,600.71 万元，同比增长 32.68%；利 润总额 12,279.47 万元，归母净利润 11,536.40 万元，分别同比增长 190.28%、 216.75%；截至 2024 年 6 月 30 日，公司资产总额 169,660.07 万元，较年初增 长 13.64%；归属于母公司所有者权益合计 84,534.58 万元，较年初增长 4.11%； 资产负债率为 34.20%。 公司各业务板块经营情况如下： 单位：万元 10,461.61 11,703.92 13,130.46 综合解决方案 产品销售 运营服务 1 / 5 二 ...

[Definitions](index=4&type=section&id=Section%201%20Definitions) This chapter defines professional terms and abbreviations of company entities used in the report, providing a foundation for understanding the content - This chapter defines professional terms and abbreviations of company entities used in the report, including the company and its subsidiaries, major shareholders, business-related terms (e.g., heavy metal wastewater, acid wastewater, hazardous waste), and technical terms (e.g., biological agents, COD), providing a basis for understanding the report content[11](index=11&type=chunk)[13](index=13&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=Section%202%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides an overview of the company's basic information and presents its key financial data and indicators for the reporting period [Company Basic Information](index=6&type=section&id=I.%20Company%20Basic%20Information) Science Environmental Protection Co., Ltd. (Science, stock code 688480) is a high-tech enterprise specializing in heavy metal pollution control, with Gao Weirong as its legal representative and registered office in Changsha, Hunan - Overview of the company's basic information, including name, stock code, legal representative, and address[16](index=16&type=chunk) - The company's shares are listed on the STAR Market of the Shanghai Stock Exchange, with the stock abbreviation "Science" and code 688480[19](index=19&type=chunk) [Key Accounting Data and Financial Indicators](index=7&type=section&id=VI.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company achieved significant performance growth with revenue up 32.68% and net profit attributable to parent company shareholders increasing by 216.75%, primarily due to the acquisition of Zijin Pharmaceutical and growth in product sales and operational services Key Accounting Data for H1 2024 | Key Accounting Data | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 356,007,135.48 Yuan | 268,317,661.23 Yuan | 32.68% | | Net Profit Attributable to Parent Company Shareholders | 115,363,959.35 Yuan | 36,421,553.07 Yuan | 216.75% | | Net Profit Attributable to Parent Company Shareholders Excluding Non-recurring Gains and Losses | 54,085,760.29 Yuan | 32,785,115.38 Yuan | 64.97% | | Net Cash Flow from Operating Activities | -881,498.88 Yuan | 27,432,765.14 Yuan | N/A | | **Indicator** | **Current Period End** | **Prior Year End** | **Period-end vs. Prior Year-end Change (%)** | | Net Assets Attributable to Parent Company Shareholders | 1,061,045,770.34 Yuan | 931,793,098.82 Yuan | 13.87% | | Total Assets | 1,696,600,727.45 Yuan | 1,493,018,387.90 Yuan | 13.64% | Key Financial Indicators for H1 2024 | Key Financial Indicators | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (Yuan/share) | 1.21 | 0.38 | 218.42% | | Basic EPS Excluding Non-recurring Gains and Losses (Yuan/share) | 0.57 | 0.35 | 62.86% | | Weighted Average Return on Net Assets (%) | 11.59% | 4.09% | increased by 7.50 percentage points | | Weighted Average ROE Excluding Non-recurring Gains and Losses (%) | 5.43% | 3.68% | increased by 1.75 percentage points | | R&D Investment as % of Operating Revenue (%) | 5.73% | 5.92% | decreased by 0.19 percentage points | - Total non-recurring gains and losses for the reporting period amounted to **61.28 million Yuan**, with the primary item being "gains from investment cost of acquiring subsidiaries, associates, and joint ventures being less than the fair value of identifiable net assets of the investee at acquisition," totaling **58.97 million Yuan**, mainly from the acquisition of Zijin Pharmaceutical[29](index=29&type=chunk)[651](index=651&type=chunk) [Management Discussion and Analysis](index=10&type=section&id=Section%203%20Management%20Discussion%20and%20Analysis) This section provides a comprehensive analysis of the company's industry, core businesses, technological advancements, competitive advantages, operational performance, and key risks [Industry and Main Business Overview in the Reporting Period](index=10&type=section&id=I.%20Industry%20and%20Main%20Business%20Overview%20in%20the%20Reporting%20Period) The company's main business is heavy metal pollution control, expanding into the specialty surfactant industry with copper extractants through the acquisition of Zijin Pharmaceutical, operating a "three-in-one" business model encompassing comprehensive solutions, product sales, and operational services - The heavy metal pollution control industry, where the company operates, is still in its development phase, characterized by low market concentration but strict qualification control and high technical entry barriers[32](index=32&type=chunk)[33](index=33&type=chunk) - In February 2024, the company completed the acquisition of Zijin Pharmaceutical, adding copper extractant products and expanding its business into the specialty surfactant sector within the fine chemical industry[32](index=32&type=chunk)[39](index=39&type=chunk) - The company's operating strategy is "three-in-one": utilizing comprehensive heavy metal pollution control solutions as the core, supported by product sales (reagents, copper extractants, integrated equipment) and operational services, forming a mutually reinforcing business structure[43](index=43&type=chunk) [Core Technologies and R&D Progress](index=16&type=section&id=II.%20Core%20Technologies%20and%20R%26D%20Progress) The company's core technologies, focusing on acid wastewater resource utilization and heavy metal wastewater treatment, remain unchanged with several reaching international leading levels, supported by a **28.37% increase in R&D investment** to **20.39 million Yuan** and a portfolio of **107 intellectual property rights** - The company's core technologies include four major series: acid wastewater resource utilization, heavy metal wastewater deep treatment and reuse, arsenic-containing hazardous waste mineralization detoxification, and heavy metal contaminated environment remediation, with several technological achievements rated as internationally leading or advanced[52](index=52&type=chunk)[53](index=53&type=chunk) R&D Investment Overview | Item | Current Period Amount | Prior Period Amount | Change (%) | | :--- | :--- | :--- | :--- | | Total R&D Investment | 20,385,125.12 Yuan | 15,879,713.32 Yuan | 28.37% | | Total R&D Investment as % of Operating Revenue (%) | 5.73% | 5.92% | decreased by 0.19 percentage points | - As of the end of the reporting period, the company cumulatively holds **107 intellectual property rights**, including **54 invention patents**, with **8 new patent applications** and **8 authorized patents** during the period[54](index=54&type=chunk)[55](index=55&type=chunk) - The company has an R&D team of **164 people**, accounting for **14.25%** of the total workforce, with **74.39%** of team members holding a bachelor's degree or higher[63](index=63&type=chunk)[71](index=71&type=chunk) [Core Competitiveness Analysis in the Reporting Period](index=22&type=section&id=III.%20Core%20Competitiveness%20Analysis%20in%20the%20Reporting%20Period) The company's core competitiveness lies in its leading technology, advantageous products like biological agents and copper extractants, "three-in-one" comprehensive service model, strong brand reputation, and high-caliber R&D and management teams - Technology and R&D advantages: The company has overcome technical challenges in acid wastewater resource utilization, deep treatment of heavy metal wastewater, and harmless disposal of arsenic-containing hazardous waste, and possesses multiple national and provincial-level scientific research platforms[64](index=64&type=chunk)[65](index=65&type=chunk) - Product advantages: Products such as biological agents, mineralizing agents, and copper extractants from subsidiary Zijin Pharmaceutical have achieved domestic substitution, broken international monopolies, and offer significant technical and environmental benefits[67](index=67&type=chunk)[68](index=68&type=chunk) - Specialized comprehensive service advantages: The company has established a "three-in-one" operating system for heavy metal pollution control, encompassing comprehensive solutions, product sales, and operational services, providing all-round services to clients[69](index=69&type=chunk) [Discussion and Analysis of Operations](index=24&type=section&id=IV.%20Discussion%20and%20Analysis%20of%20Operations) In H1 2024, the company achieved significant operational growth with **revenue reaching 356 million Yuan** (up **32.68%**) and **net profit attributable to parent company shareholders at 115 million Yuan** (up **216.75%**), driven by the full acquisition of Zijin Pharmaceutical and the completion of its production base project - In February 2024, the company acquired the remaining **61% equity** in Zijin Pharmaceutical for **183 million Yuan**, achieving **100% control**; Zijin Pharmaceutical reported a net profit of **15.09 million Yuan** in H1, a **91.29% increase** year-on-year[76](index=76&type=chunk) - The fundraising investment project "Production Base Construction Project" was completed and reached its intended usable state on June 30, 2024, with new production lines for complete sets of equipment, pressure vessels, and membrane equipment now operational[77](index=77&type=chunk) - The H2 operating plan focuses on three key business directions: heavy metal pollution control, resource utilization, and new materials, while continuously optimizing the "three-in-one" business model and advancing internationalization strategies[79](index=79&type=chunk)[80](index=80&type=chunk) [Risk Factors](index=27&type=section&id=V.%20Risk%20Factors) The company faces significant risks including macroeconomic and policy changes, intensified market competition, customer concentration, technological iteration, key personnel loss, and financial risks such as high accounts receivable and gross margin fluctuations - Industry risks: The environmental protection sector is policy-driven, and changes in policies or reduced regulatory intensity could adversely affect operations; additionally, a promising industry outlook may attract more competitors[90](index=90&type=chunk) - Operational risks: Downstream customers are primarily non-ferrous metal mining, beneficiation, and smelting enterprises, leading to high customer concentration, and significant changes in major customers' operations could adversely impact the company's business[92](index=92&type=chunk) - Financial risks: A large amount of accounts receivable puts pressure on working capital, potentially leading to bad debts if not collected promptly; additionally, gross margins for solution businesses may fluctuate due to project variations[95](index=95&type=chunk) [Key Operating Conditions in the Reporting Period](index=28&type=section&id=VI.%20Key%20Operating%20Conditions%20in%20the%20Reporting%20Period) This section details the financial status and operating results for the reporting period, highlighting synchronized growth in revenue and costs, increased expenses due to higher salaries, significant asset growth from projects and acquisitions, and a **183 million Yuan** investment to fully acquire Zijin Pharmaceutical [Analysis of Financial Statement Item Changes](index=28&type=section&id=1.%20Analysis%20of%20Financial%20Statement%20Related%20Item%20Changes) During the reporting period, the company experienced significant changes in financial statement items, with **revenue up 32.68%** and **costs up 25.23%**, while selling and administrative expenses increased due to higher salaries, and net cash flow from operating activities turned negative Major Financial Statement Item Changes | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 356,007,135.48 | 268,317,661.23 | 32.68% | | Operating Cost | 223,966,039.09 | 178,839,739.54 | 25.23% | | Selling Expenses | 21,446,887.94 | 13,861,299.28 | 54.72% | | Administrative Expenses | 26,999,485.66 | 19,796,158.01 | 36.39% | | Net Cash Flow from Operating Activities | -881,498.88 | 27,432,765.14 | N/A | [Analysis of Assets and Liabilities](index=29&type=section&id=1.%20Assets%20and%20Liabilities) As of the reporting period end, total assets reached **1.70 billion Yuan**, a **13.64% increase**, with significant shifts including a **41.53% decrease in cash** due to acquisitions and investments, and substantial increases in inventory and fixed assets due to uncompleted projects and acquisitions Major Asset and Liability Item Changes | Item Name | Current Period End Amount (Yuan) | Prior Period End Amount (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 315,202,099.62 | 539,099,788.21 | -41.53% | | Inventories | 100,978,964.15 | 32,067,638.89 | 214.89% | | Fixed Assets | 179,750,982.10 | 80,996,051.53 | 121.93% | | Contract Liabilities | 75,708,106.35 | 44,454,263.80 | 70.31% | [Analysis of Investment Status](index=31&type=section&id=(IV)%20Analysis%20of%20Investment%20Status) The most significant investment activity during the reporting period was the **183 million Yuan** acquisition of **61% equity** in Fujian Zijin Mineral Processing Reagent Co., Ltd., achieving full control and generating **59.29 million Yuan** in investment income - During the reporting period, a significant equity investment occurred with the acquisition of **61% equity** in Fujian Zijin Mineral Processing Reagent Co., Ltd. for **183 million Yuan**, achieving **100% control**, and generating an investment gain of **59.29 million Yuan** in the current period[112](index=112&type=chunk) [Analysis of Major Holding and Participating Companies](index=33&type=section&id=(VI)%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) The company holds **8 controlling subsidiaries**, including Science Engineering, Zijin Pharmaceutical, and overseas entities, with Science Engineering achieving **14.27 million Yuan** in net profit and the newly acquired Zijin Pharmaceutical reporting **15.09 million Yuan** in net profit, demonstrating strong profitability Operating Performance of Major Holding Subsidiaries H1 2024 (Unaudited) | Subsidiary Name | Net Assets (10,000 Yuan) | Net Profit (10,000 Yuan) | | :--- | :--- | :--- | | Science Engineering | 12,986.82 | 1,426.82 | | Zijin Pharmaceutical | 11,242.05 | 1,508.93 | | Serbia Subsidiary | 1,770.77 | 682.64 | | Australia Subsidiary | 674.88 | 195.92 | | Dongcheng Wastewater | 9,192.65 | 598.37 | [Corporate Governance](index=39&type=section&id=Section%204%20Corporate%20Governance) This section details the company's corporate governance structure, including shareholder meetings, changes in directors, supervisors, senior management, and core technical personnel, as well as the progress of its equity incentive plan [Shareholder Meeting Overview](index=39&type=section&id=I.%20Shareholder%20Meeting%20Overview) During the reporting period, the company held three shareholder meetings, approving key proposals such as the acquisition of Zijin Pharmaceutical equity, the 2023 annual report, profit distribution plan, and election of independent directors - The second extraordinary general meeting of shareholders in 2024 approved the "Proposal on the Acquisition of 61% Equity in Fujian Zijin Mineral Processing Reagent Co., Ltd. and Related Party Transaction"[132](index=132&type=chunk) - The 2023 annual general meeting of shareholders approved 13 proposals, including the "2023 Annual Profit Distribution Plan" and the "Proposal on the Election of Independent Directors for the Third Board of Directors"[132](index=132&type=chunk) [Changes in Directors, Supervisors, Senior Management, and Core Technical Personnel](index=40&type=section&id=II.%20Changes%20in%20Company%20Directors%2C%20Supervisors%2C%20Senior%20Management%2C%20and%20Core%20Technical%20Personnel) During the reporting period, Mr. Xiao Haijun resigned as an independent director, and Mr. Qu Maohui was elected as the new independent director, with no other changes to directors, supervisors, senior management, or core technical personnel - Independent director Xiao Haijun resigned, and Qu Maohui was elected as the new independent director[135](index=135&type=chunk) [Equity Incentive Plan](index=41&type=section&id=IV.%20Company%20Equity%20Incentive%20Plan) During the reporting period, the company advanced its 2023 Restricted Stock Incentive Plan, granting **168,500 reserved restricted shares** to **14 grantees** and completing the vesting registration for **499,512 shares** from the first grant - On April 2, 2024, the company granted **168,500 reserved restricted shares** to **14 grantees** at an exercise price of **13.93 Yuan/share**[137](index=137&type=chunk) - The company completed the share registration for the first vesting period of the 2023 Restricted Stock Incentive Plan's initial grant, with a total of **499,512 shares vested**[137](index=137&type=chunk) [Environmental and Social Responsibility](index=42&type=section&id=Section%205%20Environmental%20and%20Social%20Responsibility) This section outlines the company's environmental protection efforts, including investments, compliance of key polluting subsidiaries, and initiatives to reduce carbon emissions [Environmental Information Overview](index=42&type=section&id=I.%20Environmental%20Information%20Overview) The company invested **5.06 million Yuan** in environmental protection during the reporting period, with key polluting subsidiaries achieving compliant emissions and implementing emergency plans, while also reducing **663 tons of CO2 equivalent** through initiatives like solar power and geothermal heating - During the reporting period, the company's environmental protection investment amounted to **5.06 million Yuan**[140](index=140&type=chunk) - Subsidiaries Hengyang Songen, Ningxiang Dongcheng Wastewater, and Fujian Zijin Pharmaceutical are designated key polluting units, all of which have constructed and operated pollution control facilities as required, developed emergency plans, and achieved compliant emissions during the reporting period[141](index=141&type=chunk)[143](index=143&type=chunk)[146](index=146&type=chunk)[149](index=149&type=chunk)[153](index=153&type=chunk) - The company implemented measures such as photovoltaic power generation, carbon reduction technologies, and geothermal auxiliary heating, reducing carbon dioxide equivalent emissions by **663 tons** during the reporting period[159](index=159&type=chunk) [Significant Matters](index=47&type=section&id=Section%206%20Significant%20Matters) This section covers major events including significant related party transactions, particularly the acquisition of Zijin Pharmaceutical, and the progress of the company's raised funds utilization [Significant Related Party Transactions](index=61&type=section&id=X.%20Significant%20Related%20Party%20Transactions) During the reporting period, the company engaged in significant related party transactions, primarily the **183 million Yuan** acquisition of **61% equity** in Fujian Zijin Mineral Processing Reagent Co., Ltd. from Zijin Mining Group Co., Ltd., alongside ongoing operational transactions for services and procurement - The company acquired **61% equity** in its associate, Fujian Zijin Mineral Processing Reagent Co., Ltd., for **183 million Yuan** from related party Zijin Mining; post-transaction, the company holds **100% equity** in Zijin Pharmaceutical[218](index=218&type=chunk) - The company has ongoing operational related party transactions with Zijin Mining and its subsidiaries; in 2024, estimated sales of goods or services to them are **450 million Yuan**, with **82.70 million Yuan** incurred in the reporting period, and estimated purchases of goods are **15 million Yuan**, with **5.31 million Yuan** incurred[217](index=217&type=chunk) [Progress of Raised Funds Utilization](index=63&type=section&id=XII.%20Explanation%20of%20Progress%20in%20Use%20of%20Raised%20Funds) As of the reporting period end, the company's net proceeds from its IPO totaled **455 million Yuan**, with **122 million Yuan** cumulatively invested in committed projects (a **30.48% progress**), including the completed "Environmental Equipment Production Base Project" and the "R&D Center Expansion Project" at **57.07% completion** Overall Utilization of Raised Funds (Unit: 10,000 Yuan) | Item | Amount | | :--- | :--- | | Net Proceeds from Offering After Issuance Expenses | 45,469.39 | | Total Committed Investment Project Funds | 25,000.00 | | Cumulative Investment as of Reporting Period End | 12,170.64 | | Overall Progress (%) | 30.48% | - The fundraising investment project "Changsha Science Environmental Engineering Technology Co., Ltd. Complete Environmental Equipment Production Base Project" reached its intended usable state on June 30, 2024[226](index=226&type=chunk)[228](index=228&type=chunk) [Share Changes and Shareholder Information](index=68&type=section&id=Section%207%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in the company's share capital due to equity incentives and provides an overview of its shareholder structure, including major shareholders and the actual controller [Share Capital Changes](index=68&type=section&id=I.%20Share%20Capital%20Changes) During the reporting period, the company's total share capital increased by **499,512 shares** to **95,326,179 shares** due to the vesting of the first grant under the 2023 Restricted Stock Incentive Plan - During the reporting period, due to equity incentive vesting, the company's total share capital increased from **94,826,667 shares** to **95,326,179 shares**, with an addition of **499,512 shares**[236](index=236&type=chunk)[237](index=237&type=chunk) [Shareholder Information](index=69&type=section&id=II.%20Shareholder%20Information) As of the reporting period end, the company had **3,449 common stock shareholders**, with Gao Weirong (**25.25%**) and Zijin Mining Zifeng (Xiamen) Investment Partnership (**21.11%**) as the top two shareholders, and Gao Weirong, Gao Liangyun, and Gao Shihui acting in concert as the actual controllers - As of the end of the reporting period, the company had a total of **3,449 common stock shareholders**[238](index=238&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shares Held at Period End | Proportion (%) | | :--- | :--- | :--- | | Gao Weirong | 24,065,685 | 25.25% | | Zijin Mining Zifeng (Xiamen) Investment Partnership | 20,120,000 | 21.11% | | Gao Liangyun | 6,244,000 | 6.55% | | Tan Xiaolin | 4,080,000 | 4.28% | | Jiang Guomin | 2,819,000 | 2.96% | [Financial Report](index=76&type=section&id=Section%2010%20Financial%20Report) This section presents the company's unaudited financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in owners' equity, along with detailed notes on key items and changes in consolidation scope [Financial Statements](index=76&type=section&id=II.%20Financial%20Statements) This section provides unaudited consolidated and parent company financial statements, showing growth in total assets and net assets, significant increases in revenue and profit, negative cash flows from operating and investing activities, and positive cash flow from financing activities - The consolidated balance sheet shows total assets of **1.70 billion Yuan** and net assets attributable to parent company shareholders of **1.06 billion Yuan** as of the period end[258](index=258&type=chunk)[260](index=260&type=chunk) - The consolidated income statement shows total operating revenue of **356 million Yuan** and net profit of **118 million Yuan** for H1, of which **115 million Yuan** is attributable to parent company shareholders[266](index=266&type=chunk)[267](index=267&type=chunk) - The consolidated cash flow statement shows a net cash outflow from operating activities of **0.88 million Yuan**, a net cash outflow from investing activities of **290 million Yuan**, and a net cash inflow from financing activities of **47.20 million Yuan**[274](index=274&type=chunk)[275](index=275&type=chunk) [Notes to Consolidated Financial Statement Items](index=122&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes on key consolidated financial statement items, including **315 million Yuan** in cash (with **41.48 million Yuan** restricted), **432 million Yuan** in accounts receivable, a significant increase in inventory, **165 million Yuan** in new goodwill from the Zijin Pharmaceutical acquisition, and a balanced revenue contribution across comprehensive solutions, product sales, and operational services - Cash and cash equivalents at period-end totaled **315 million Yuan**, of which **41.48 million Yuan** was restricted, primarily for bill deposits, letter of guarantee deposits, and time deposits[392](index=392&type=chunk) - Accounts receivable at period-end had a book balance of **484 million Yuan**, with a bad debt provision of **51.42 million Yuan**, resulting in a carrying value of **432 million Yuan**; the top five customers' accounts receivable and contract assets collectively accounted for **25.92%** of the total[405](index=405&type=chunk)[412](index=412&type=chunk) - Due to the acquisition of Fujian Zijin Mineral Processing Reagent Co., Ltd., **165 million Yuan** in goodwill was newly recognized in the current period[463](index=463&type=chunk) Composition of Main Business Revenue (Current Period) | Business Type | Revenue (Yuan) | Cost (Yuan) | | :--- | :--- | :--- | | Heavy Metal Pollution Control Comprehensive Solutions | 104,616,111.48 | 72,619,454.51 | | Product Sales | 117,039,151.77 | 64,336,612.92 | | Operational Services | 131,304,578.55 | 85,707,240.34 | [Changes in Consolidation Scope](index=177&type=section&id=IX.%20Changes%20in%20Consolidation%20Scope) During the reporting period, the company completed a business combination not under common control by acquiring **61% equity** in Fujian Zijin Mineral Processing Reagent Co., Ltd. for **183 million Yuan** on February 4, 2024, resulting in a total merger cost of **300 million Yuan** and recognition of **165 million Yuan** in goodwill - A business combination not under common control occurred in the current period, with the acquisition of **61% equity** in Fujian Zijin Mineral Processing Reagent Co., Ltd. on February 4, 2024, gaining control and including it within the scope of consolidated financial statements[567](index=567&type=chunk) - The total merger cost for this acquisition was **300 million Yuan**, and after deducting the fair value share of identifiable net assets acquired (**135 million Yuan**), **165 million Yuan** in goodwill was recognized[568](index=568&type=chunk)

证券代码：688480 证券简称：赛恩斯 公告编号：2024-040 赛恩斯环保股份有限公司 第三届监事会第十二次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 赛恩斯环保股份有限公司（以下简称"公司"）第三届监事会第十二次会 议于 2024 年 8 月 23 日以现场及通讯相结合的方式召开，会议召开地点为公司 会议室。本次会议通知于 2024 年 8 月 13 日送达全体监事。会议由监事会主席 姚晗女士主持。会议应到监事 3 人，实到监事 3 人。本次会议的召集和召开、 表决方式、决议内容符合《中华人民共和国公司法》《上海证券交易所科创板 股票上市规则》等相关法律法规、规范性文件及《公司章程》的相关规定，会 议决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于公司 2024 年半年度报告及其摘要的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 具体内容见公司披露于上海证券交易所网站(www.sse.com.cn)的《赛恩斯 环保股份有限公司 2024 年半年 ...